Accelerate to discover
Related topics
Theranostics: From Mice to Men and Back
Jun 25, 2024
Recorded webinar
Presenters: Prof. Dr. Ken Herrmann and Prof. Dr. Katharina Lückerath – Moderator: Hannah Notebaert
Orion 2024 AACR poster: 17-plex single-step stain and imaging of cell Lung Carcinoma
Jun 21, 2024
RareCyte Orion is a benchtop, high resolution, whole slide multimodal imaging instrument. A combination of quantitative...
Hypoxia in the Tumor Immune Microenvironment (TIME)
Jun 6, 2024
Thursday, 11 July 2024, 16:00 CET | 10:00 EST
Zaver M. Bhujwalla, PhD
X-RAD 320 for irradiation therapy during quantifying study for in vivo collagen reorganization
Jun 5, 2024
Quantifying in vivo collagen reorganization during immunotherapy in murine melanoma with second harmonic generation...
Use of MRI and microCT to evaluate gene therapy for the treatment of discogenic back pain
Jun 4, 2024
MRI images were obtained using the 9.4T Bruker BioSpec system, equipped with 40 mm 1H quadrature volume resonator, and...
Exosome-Mediated Delivery of Small Molecules, RNA & DNA for Development of Novel Cancer Therapeutics
Jun 3, 2024
Disha Moholkar of University of Louisville's Gupta Lab
Tuesday, June 11, 2024, 6:30 PM...
Emulate in vivo conditions – introduce shear flow to your experiments with BioFlux system
May 27, 2024
Most research is still conducted in vitro without the presence of flow. We use the BioFlux System to give you the...
High-frequency Ultrasound System For Preclinical Imaging
May 13, 2024
The Prospect T1 is an innovative high-frequency ultrasound system designed specifically for in vivo preclinical imaging...
Jun 23, 2021
Non-Hodgkin’s lymphoma (NHL) is one of the most common types of hematologic malignancies in the United States. In 2018, 75,000 Americans were newly diagnosed with NHL, and an estimated 20,000 died from it. Anti-CD20 (α-CD20) monoclonal antibodies (Abs), such as rituximab, have revolutionized the treatment of NHL, but 35 to 40% of patients with NHL still relapse after rituximab-containing therapy, such as R-CHOP. Some data indicate that low antigen density, antigen shedding, and/or internalization of CD20 antigens in malignant lymphoma cells could be responsible for resistance to rituximab. For this reason, Abs that target other common lymphoma markers have been investigated.
Do you want to learn more? Read the whole article, or just ask us!
Related technologies: Fluorescence, luminescence, X-ray, radiographic imaging
Get more info
Brand profile
Spectral Instruments Imaging manufactures instruments for preclinical optical (bioluminescent, fluorescent) and X-ray imaging.
More info at:
https://spectralinvivo.com/
BioFocus newsletter
Register to receive Brand new technology development, Important product updates, Interesting scientific events and more!
BioTech a.s. © 2014
Designed & developed by imagineit
Technologies
